Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. - Wikidata - awgldk - TriplyDB

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

http://www.wikidata.org/entity/Q37718248

about

Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration.Redox biology and the interface between bioenergetics, autophagy and circadian control of metabolism High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria Cancer and neurodegeneration: between the devil and the deep blue sea.Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.Mechanism of oxidative stress in neurodegeneration.Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism.Role of NAD(+), Oxidative Stress, and Tryptophan Metabolism in Autism Spectrum Disorders.Mitophagy and Parkinson's disease: the PINK1-parkin link.Modeling mitochondrial encephalomyopathy in Drosophila.Impaired mitochondrial function in psychiatric disorders.Mitochondria, calcium-dependent neuronal death and neurodegenerative disease.Mitochondria and the central nervous system: searching for a pathophysiological basis of psychiatric disorders.Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam.Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.Effect of β-amyloid (25-35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons.Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation.Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia.Novel biomarkers of metabolic dysfunction is autism spectrum disorder: potential for biological diagnostic markers.Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.

P2860

Q27300826-74F66B1D-71A3-47F7-B241-62BCEB92BF3D Q28394996-36A818AC-0BB7-4978-AE21-5EDA6082071F Q28479257-4C9A0663-9E53-4460-BDAF-B773DE813B98 Q33784620-E841F320-D8E1-4A22-AE3B-7332800DA0AD Q34299928-BBEE6C60-5EC9-4141-A118-DF1348FB5C48 Q35315489-C5224FDD-0EE2-4FAA-8D42-C0A41F38EA40 Q35996874-2686046A-1AC1-44A7-B8DC-B2FA8AB17D02 Q36820898-CD3B9921-8521-4699-B7B3-8E4B95F5451E Q37059666-BD39B6F8-22F0-4EE4-8DA1-D69355DEC249 Q37587126-554204DA-CDD1-4C84-9FF0-09B2BA30BB4C Q37753231-05E060C6-067F-4450-88EE-DBB2D52C9ECA Q38003304-578AC218-8BE6-4F4C-B60E-90425880188F Q38012067-8DFC51F0-E06C-4AB2-92CD-7728D484B975 Q38213177-C590AC3A-2999-4DB9-8389-89A657890108 Q39014966-546795BA-E923-4E72-93B3-92ACC9C3CFD3 Q39092856-44027D52-CC01-47CE-A884-11380F711132 Q42081903-B5120F1E-9547-4574-B983-9D1910E3A1DE Q44147847-DC5B76B6-D2BB-472F-85D2-337B0A50E8AC Q46142299-4C103F54-19BC-458A-9C3C-6FA583B1E321 Q47125617-571A7A2B-DD46-40F9-A7C8-EF953FDDB6CE Q47730175-517A0E8C-99A9-4270-93FE-957A1A622E79 Q49843059-98173560-0E6D-41FA-989F-3429B182FA2B

P2860

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

http://www.wikidata.org/entity/Q37718248

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@en

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@nl

type

label

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@en

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@nl

prefLabel

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@en

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.

@nl

P1433

Q37718248-CCBB677C-A00A-47F0-A97F-484C84C888C2

P1476

Q37718248-917397C3-E0D1-4B9F-8235-19E718325BC5

P2093

Q37718248-01F8A8E0-5458-4CF7-A129-277E3697B21F

Q37718248-323C7CFE-B9EC-40D6-BED8-0763AA64C781

Q37718248-76482156-4B9A-489B-9604-8F8C7A781E62

Q37718248-D30573E9-BBC6-412A-A112-63AF36530912

P2860

Q37718248-0047F762-3079-4420-A2AA-D09E781A01F5

Q37718248-024D6E54-5127-4C05-B892-61E9762BD3D9

Q37718248-056E0CFB-76A4-4AC8-9A56-1F8191CEF26B

Q37718248-087FBA41-ECD7-433F-9D79-9E577E3836C6

Q37718248-0AF2FC46-CB32-4D0C-B3B4-6759709DFBE7

Q37718248-0B5C132E-7E6C-458B-BCBB-4B92DC7D977F

Q37718248-0DD02B11-DCD3-49CF-ABA9-6388E8F78093

Q37718248-11EC7EE8-826D-477A-AC1B-35954000CB72

Q37718248-1402CA92-A886-43E1-9FF1-C8CD7E2B98B3

Q37718248-1705AB2F-687F-47B2-B841-8254425A0789

P304

Q37718248-ACD02189-F076-4684-AD59-58AF4F3A6B5C

P31

Q37718248-8F0478A9-089A-4E24-BA31-B333C10DC7E8

P356

Q37718248-D3480505-2E06-4F8F-BA98-D8345A4F095A

P407

Q37718248-A64A48CD-895C-4AB2-833A-E24844F2D1BB

P433

Q37718248-5AAB8D6E-0EC0-4376-B088-F446B9DB4BD6

P478

Q37718248-C047D5D1-87E1-4195-B642-733A197F0FE3

P50

Q37718248-28FE6D9F-19CE-4FA7-BCFC-C3F22B29D553

Q37718248-6AD7E91E-650B-4D14-81EF-5F86AC7B108A

P577

Q37718248-74BC87DB-E81F-4249-A092-E5123BA48927

P698

Q37718248-A36C1ADE-5643-4604-B462-584D1210A68A

P921

Q37718248-12DA0709-E26B-4BD7-A3C3-ECE5389210F8

Q37718248-EB5879B4-40DD-4AB5-AE1D-261B13E76244

P356

14728221003730434

P1433

Expert Opinion on Therapeutic Targets

P1476

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II

@en

P2093

Emma Deas

http://www.w3.org/2001/XMLSchema#string

Hélène Plun-Favreau

http://www.w3.org/2001/XMLSchema#string

Sonia Gandhi

http://www.w3.org/2001/XMLSchema#string

Victoria S Burchell

http://www.w3.org/2001/XMLSchema#string

P2860

Free radicals and antioxidants in normal physiological functions and human disease

Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease

A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness

PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1

Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation

Localization of LRRK2 to membranous and vesicular structures in mammalian brain

Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission

The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis

P304

497-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728221003730434

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas W. Wood

Andrey Y Abramov

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20334487

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration